
Surface Oncology Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Surface Oncology Inc
Access all reports
Surface Oncology Inc is a clinical-stage immuno-oncology company dedicated to the development of novel antibody therapies for the treatment of cancer. Its focus lies in creating and advancing treatments designed to modify the tumor microenvironment, thereby supporting and sustaining anti-tumor immune responses. The company's product portfolio includes SRF388, aimed at treating diseases such as renal cell carcinoma, hepatocellular carcinoma, and non-small cell lung cancer, as well as SRF617 for various tumors including gastric cancer, prostate cancer, PD-(L)1 relapsed cancer, and pancreatic cancer. Surface Oncology is also working on SRF114, NZV930, and GSK4381562 antibodies, alongside conducting research and development activities and pre-clinical studies. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the Nasdaq.
Latest articles
)
Moncler: From the Mountains to the Runway
The story of Moncler, all the way from its beginnings in the Alps to its journey to some of the most prestigious runways in the world.
16 Apr 2025
)
eToro: Innovation, Growth, and IPO Plans
eToro was founded in 2007 and has grown into a global trading platform with over 40 million users and an extensive offering across several asset classes.
10 Apr 2025
)
Yum! Brands: The Company Behind Pizza Hut, KFC, and Taco Bell
Yum! Brands started at PepsiCo in the 1970s and is home to some of the most well-known brands in the world, such as Pizza Hut, KFC, and Taco Bell.
9 Apr 2025
Ticker symbol
SURF
Country
🇺🇸 United States